Compare
Aptevo Therapeutics Inc. vs Skye Bioscience, Inc. vs BeyondSpring Inc. vs Biofrontera Inc.
| Latest fiscal year | Aptevo Therapeutics Inc. APVORevenue covers only part of its income (partial revenue) | Skye Bioscience, Inc. SKYE | BeyondSpring Inc. BYSI | Biofrontera Inc. BFRI |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | n/a | n/a | $0 | $41.70M |
| Revenue growth (YoY) | n/a | n/a | n/a | +11.7% |
| Gross margin | n/a | n/a | n/a | n/a |
| Operating margin | n/a | n/a | n/a | -27.2% |
| Net margin | n/a | n/a | n/a | -25.3% |
| Net income | -$25.97M | -$55.92M | -$1.01M | -$10.54M |
| EPS (Diluted) | -$87.27 | -$1.41 | n/a | -$1.04 |
| Operating cash flow | -$25.59M | -$43.06M | -$19.77M | -$13.36M |
| Free cash flow | n/a | -$43.07M | -$19.82M | -$13.36M |
| Cash & equivalents | $21.62M | $5.88M | $7.79M | $6.39M |
| Total assets | $27.19M | $28.31M | $25.93M | $28.56M |
| Total liabilities | $9.81M | $8.29M | $49.92M | $18.08M |
| Shareholders' equity | $17.38M | $20.02M | -$23.99M | $10.48M |
| Return on year-end equity | -149.4% | -279.3% | n/a | -100.5% |
| Shares outstanding | 997.8K | 33.38M | n/a | 11.65M |
Revenue, most recent five fiscal years
| Fiscal year | Aptevo Therapeutics Inc. | Skye Bioscience, Inc. | BeyondSpring Inc. | Biofrontera Inc. |
|---|---|---|---|---|
| Latest | n/a | n/a | $0 Ended 2025-12-31 | $41.70M Ended 2025-12-31 |
| 1 year earlier | n/a | n/a | $0 Ended 2024-12-31 | $37.32M Ended 2024-12-31 |
| 2 years earlier | n/a | n/a | $0 Ended 2023-12-31 | $34.07M Ended 2023-12-31 |
| 3 years earlier | n/a | n/a | $1.35M Ended 2022-12-31 | $28.67M Ended 2022-12-31 |
| 4 years earlier | n/a | n/a | $1.35M Ended 2021-12-31 | $24.10M Ended 2021-12-31 |